Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01166646 · ClinicalTrials.gov registry record · Phase 2
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
A Phase 2 study, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01166646 is a Phase 2 study that has completed, run by Therapeutics. The registered enrollment target is 43 participants.
The verdict
NCT01166646, a Phase 2 study, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the investigational lotion is an effective treatment of moderate to severe plaque psoriasis in comparison to an approved cream.
Interventions
- DRUG Halobetasol Proprionate Lotion 0.05%
- DRUG Halobetasol Proprionate Cream 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01166646
The ClinicalTrials.gov registry entry for NCT01166646 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Halobetasol Proprionate Lotion 0.05% is the first listed.
NCT01166646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01166646 about?
NCT01166646 is a clinical study titled "Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis". The purpose of this study is to determine whether the investigational lotion is an effective treatment of moderate to severe plaque psoriasis in comparison to an approved cream.
What is the current status of trial NCT01166646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2010-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01166646?
The interventions under investigation include: Halobetasol Proprionate Lotion 0.05% (DRUG), Halobetasol Proprionate Cream 0.05% (DRUG).
Who is sponsoring clinical trial NCT01166646?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.